trending Market Intelligence /marketintelligence/en/news-insights/trending/wt0vjpi-dkyktm8efoxryw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

FDA rejects Innocoll's application for postsurgical pain drug

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles


Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

FDA rejects Innocoll's application for postsurgical pain drug

Innocoll Holdings PLC received a rejection from the U.S. FDA relating to an application for XARACOLL, the company's product candidate to treat postsurgical pain.

In a preliminary review, the FDA indicated that the application submitted in October was not sufficiently complete to permit a substantive review. It also indicated, among other things, that the drug should be characterized as a drug/device combination, which would require Innocoll to submit additional information.

The company will request a Type A meeting with the FDA to respond to several issues believed to be addressable and seek clarification of what additional information, if any, will be required.